Most Accessed Articles
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 2013; 13(3): 326-346.Ziyad Binkhathlan and Afsaneh Lavasanifar
DOI: 10.2174/15680096113139990076
Multimodal HDAC Inhibitors with Improved Anticancer Activity
, 2018; 18(1): 39-56.Rainer Schobert and Bernhard Biersack*
DOI: 10.2174/1568009617666170206102613
Potential Anti-cancer Drugs Commonly Used for Other Indications
, 2015; 15(1): 35-52.Veronika Hanusova, Lenka Skalova, Vera Kralova and Petra Matouskova
DOI: 10.2174/1568009615666141229152812
Lung Cancer Stem Cells: An Epigenetic Perspective
, 2018; 18(1): 16-31.Samriddhi Shukla, Sajid Khan, Sonam Sinha and Syed Musthapa Meeran*
DOI: 10.2174/1568009617666170206104623
Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
, 2018; 18(4): 306-327.Heena Singla, Anjana Munshi*, Raja Paramjit Singh Banipal and Vinod Kumar*
DOI: 10.2174/1568009617666170623122213
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
, 2003; 3(1): 1-19.R. Z. Yusuf, Z. Duan, D. E. Lamendola, R. T. Penson and M. V. Seiden
DOI: 10.2174/1568009033333754
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
, 2015; 15(8): 665-683.Otília Menyhart, Libero Santarpia and Balazs Gyorffy
DOI: 10.2174/156800961508151001101742
The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
, 2018; 18(4): 355-364.Dearbhaile C. Collins, Maxime Chenard-Poirier and Juanita S. Lopez*
DOI: 10.2174/1568009617666170927114440
Transforming Cancer Epigenetics Using Nutritive Approaches and Noncoding RNAs
, 2018; 18(1): 32-38.Centdrika R. Dates and Trygve O. Tollefsbol*
DOI: 10.2174/1568009617666170203165326
Webmaster Contact: info@benthamscience.org